Condition
BCG Vaccination
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
Early P 1 (1)
Trial Status
Completed3
Unknown1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06628544Early Phase 1CompletedPrimary
Trained Immunity in Fungal Infection and Its Mechanism
NCT04384614Withdrawn
Covid-19 In Tunisia: An Observational Cross-Sectional Registry Study
NCT04347876Unknown
Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?
NCT04064554Not ApplicableCompleted
Clinical Study to Evaluate Safety and Immunogenicity of Bacillus Calmette-Guerin (BCG) Delivery Via Novel Micronjet600 Device Compared to Those Via Conventional Needle
NCT02175420Not ApplicableCompletedPrimary
Role of BCG as Booster Vaccination
Showing all 5 trials